GlassScriptPhysician profile
Christina Rose Lavery
NPI 1285228007
$3,697.64
in general payments reported to CMS, 2019-2025
37 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.41 · 2022: $1,308 · 2023: $1,989 · 2024: $232 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.86 |
| Education | $320.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $289.91 | 2022-2023 | Jakafi |
| Janssen Biotech, INC. | $275.91 | 2022-2023 | Erleada, Darzalex, Tecvayli |
| Lilly USA, LLC | $268.91 | 2022-2023 | Verzenio, Jaypirca |
| Abbvie INC. | $263.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $238.76 | 2022-2023 | Calquence |
| Pfizer INC. | $224.52 | 2022-2025 | |
| Daiichi Sankyo INC. | $168.24 | 2022-2023 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $160.42 | 2023 | Imbruvica, Epkinly |
| Eisai INC. | $153.48 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $149.00 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Teva Pharmaceuticals USA, INC. | $122.49 | 2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $118.45 | 2022-2023 | Ninlaro |
| Array Biopharma INC | $112.94 | 2022-2023 | Mektovi, Lorbrena, Braftovi |
| Antares Pharma, INC. | $112.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.02 | 2022-2025 | Opdualag, Opdivo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $100.62 | 2022-2023 | Pomalyst, Reblozyl, Opdualag |
| Genentech USA, INC. | $96.49 | 2023 | Tecentriq, Lunsumio, Polivy |
| Gilead Sciences, INC. | $96.24 | 2022-2023 | |
| Foundation Medicine, INC. | $85.75 | 2023 | |
| Karyopharm Therapeutics INC. | $61.22 | 2022-2023 | Xpovio |
| Glaxosmithkline, LLC. | $56.82 | 2022-2024 | Ojjaara, Shingrix |
| Tersera Therapeutics LLC | $39.34 | 2023 | Zoladex |
| Puma Biotechnology, INC. | $38.16 | 2022-2023 | |
| Exelixis INC. | $35.67 | 2022-2023 | Cabometyx |
| Seagen INC. | $34.33 | 2023 | Adcetris, Tukysa |
| Genzyme Corporation | $33.12 | 2023 | |
| Blueprint Medicines Corporation | $30.00 | 2022 | |
| Sobi, INC | $29.79 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $28.87 | 2022-2023 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $27.09 | 2023 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.76 | 2023 | Gilotrif |
| Amgen INC. | $21.91 | 2023 | Kyprolis |
| Regeneron Healthcare Solutions, INC. | $21.90 | 2023 | Libtayo |
| Kyowa Kirin, INC. | $17.96 | 2023 | Poteligeo |
| G1 Therapeutics, INC. | $17.02 | 2023 | Cosela |
| Taiho Oncology, INC. | $16.46 | 2022 | |
| Global Blood Therapeutics, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Lavery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.